Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

thyroid neoplasms/tyrosine

Länken sparas på Urklipp
Sida 1 från 33 resultat

Cancer and Blood Pressure Management, CARISMA Study

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
PRIMARY OBJECTIVE: I. To determine the feasibility of an intensive (systolic blood pressure [SBP] < 120 mmHg) "Intervention" versus standard care (SBP < 140 mmHg) "Non-Intervention" approach to blood pressure (BP) control in metastatic renal cell and thyroid cancer patients initiating
Even though the prognosis of advanced GIST has been tremendously improved by the introduction of tyrosine kinase inhibitors, the vast majority of patients will develop secondary resistance to these agents. The therapeutic options of patients with advanced GIST with resistance (or intolerance) to

Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This study is design to prospectively investigate the safety and efficacy of apatinib in downsizing primary tumors and metastatic lesions in patients with metastatic and advanced differentiated thyroid cancers before RAI Treatment. Standard treatment of thyroid cancer includes thyroidectomy, RAI

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Soft tissue sarcoma (STS) is a relatively rare type of malignant tumor. For patients with recurrent/distant metastasis/unresectable advanced soft tissue sarcoma, chemotherapy with doxorubicin and ifosfamide is the standard treatment, but the effect is limited. Targeted drugs represented by

Rehabilitation Program in Patients With Acromegaly

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Acromegaly is a rare, chronic, disabling disease of endocrine origin that causes several debilitating systemic dysfunctions due to the excessive production of growth hormone (GH) and insulin-like growth factor I (IGF-I) (Gadelha et al., 2017). In 98% of cases, the disease is caused by a sporadic

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Population: Patients with advanced progressive 131I-refractory DTC or MTC will be enrolled to this study. Forty-five patients responding to TKI therapy (defined as 50% drop in tumor marker level within the first two months of treatment) will be randomized to receive TKI therapy either through

Cabozantinib in Advanced Salivary Gland Cancer Patients

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Rationale: Salivary gland cancer (SGC) is a rare cancer with 24 histological subtypes. Treatment options for locally advanced and/or metastatic SGC are limited. The tyrosine kinase inhibitor cabozantinib suppresses tumor growth, angiogenesis, and metastasis, and has been approved for renal cell

Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.The study is a randomised,multicentre,double-blind,placebo-controlled,study.

Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
See brief summary

Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Bladder cancer is the 9th most common cancer worldwide, with around 429.800 new cases diagnosed in 2012 and the 5th most common cancer in Europe, with more than 151.000 new cases diagnosed in 2012. Relating mortality figures, bladder cancer is the 13th most common cause of cancer death worldwide,

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This is a Phase I/II research study, which means that researchers are testing different doses of the drug alectinib in participants with cancer to evaluate its safety, determine a safe dosage range, and identify side effects. The FDA (the U.S. Food and Drug Administration) has approved alectinib as

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Primary Outcome Measure: Progression free survival of apatinib in RAIR-DTC. Secondary Outcome Measures: Disease control rate, objective response rate, duration of response, changes of Tg and TgAb level in serum, overall survival, side effects and quality of life.

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This phase 2 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.The study is a randomised,multicentre,open-label study.

Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Carcinomas of the salivary glands (SGCs) are rare, (less than 1% of all cancers of the head and neck and include more than 20 malignant histotypes. They can occur both in major and minor salivary glands, are locally aggressive, demonstrating invasiveness that leads to involvement of the facial
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge